Literature DB >> 15364816

Sensing tissue ischemia: another new function for capsaicin receptors?

Hui-Lin Pan1, Shao-Rui Chen.   

Abstract

BACKGROUND: Chest pain is a hallmark of myocardial ischemia, but its underlying signaling mechanisms remain poorly understood. The capsaicin receptor, vanilloid receptor-1 (VR1), is an important cation channel present on primary nociceptive neurons. We have shown that the VR1 is expressed on sensory nerve endings of the heart. In the present study, we determined the role of VR1s in activation of cardiac spinal afferent nerves caused by myocardial ischemia. METHODS AND
RESULTS: Single-unit activity of cardiac afferents was recorded from the sympathetic chain of anesthetized ferrets. Cardiac afferents responded to 5 minutes of regional myocardial ischemia and topical application of 10 microg/mL bradykinin in a reproducible manner. Topical application of a specific VR1 antagonist, iodoresiniferatoxin (50 micromol/L), to the receptive field of afferents produced a large attenuation of the firing activity of cardiac afferents caused by myocardial ischemia. Iodoresiniferatoxin also significantly reduced the afferent response to bradykinin applied to the receptive field. Furthermore, treatment with a VR1 channel blocker, ruthenium red (200 micromol/L), had a similar inhibitory effect on the afferent responses to myocardial ischemia and bradykinin.
CONCLUSIONS: This study provides the first functional evidence that ischemic stimulation of cardiac spinal afferent nerves is mediated through VR1s. The VR1 on the cardiac sensory nerve may function as a molecular sensor to detect tissue ischemia and activate cardiac nociceptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15364816     DOI: 10.1161/01.CIR.0000142618.20278.7A

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  35 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  No pain, no gain: the useful function of angina.

Authors:  Roberto Bolli; Ahmed Abdel-Latif
Journal:  Circulation       Date:  2005-12-06       Impact factor: 29.690

3.  Blocking the transient receptor potential vanilloid-1 does not reduce the exercise pressor reflex in healthy rats.

Authors:  Guillaume P Ducrocq; Juan A Estrada; Joyce S Kim; Marc P Kaufman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2019-07-31       Impact factor: 3.619

Review 4.  Neuromodulation Approaches for Cardiac Arrhythmias: Recent Advances.

Authors:  Veronica Dusi; Ching Zhu; Olujimi A Ajijola
Journal:  Curr Cardiol Rep       Date:  2019-03-18       Impact factor: 2.931

Review 5.  TRP channels as sensors of oxygen availability.

Authors:  Tomohiro Numata; Nozomi Ogawa; Nobuaki Takahashi; Yasuo Mori
Journal:  Pflugers Arch       Date:  2013-02-17       Impact factor: 3.657

6.  TRPV1: contribution to retinal ganglion cell apoptosis and increased intracellular Ca2+ with exposure to hydrostatic pressure.

Authors:  Rebecca M Sappington; Tatiana Sidorova; Daniel J Long; David J Calkins
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

7.  N-oleoyldopamine, a novel endogenous capsaicin-like lipid, protects the heart against ischemia-reperfusion injury via activation of TRPV1.

Authors:  Beihua Zhong; Donna H Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-06-20       Impact factor: 4.733

8.  Successful TRPV1 antagonist treatment for cardiac hypertrophy and heart failure in mice.

Authors:  Jaime S Horton; Cadie L Buckley; Alexander J Stokes
Journal:  Channels (Austin)       Date:  2012-12-06       Impact factor: 2.581

9.  Cardiac innervation and sudden cardiac death.

Authors:  Masaki Ieda; Keiichi Fukuda
Journal:  Curr Cardiol Rev       Date:  2009-11

Review 10.  Endocannabinoids and the heart.

Authors:  C Robin Hiley
Journal:  J Cardiovasc Pharmacol       Date:  2009-04       Impact factor: 3.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.